Strong Price Performance and Market Context
On 11 Dec 2025, Venus Remedies recorded an intraday peak of Rs.825, marking its highest price level in the past year and an all-time high for the company. The stock opened with a gap up of 3.62% and closed with a day’s gain of 4.76%, outperforming its sector by 3.69%. This price action follows two consecutive days of gains, during which the stock delivered an 8.8% return, signalling sustained buying interest and positive momentum.
Venus Remedies is currently trading above all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating a strong technical position. This alignment of moving averages often suggests a bullish trend and investor confidence in the stock’s near-term trajectory.
Sector and Broader Market Environment
The broader market, represented by the Sensex, experienced a slight decline of 0.21% on the same day, closing at 84,213.06 points after a flat opening. Despite this, the Sensex remains close to its own 52-week high, just 2.31% shy of the peak at 86,159.02. The index is trading above its 50-day moving average, which itself is positioned above the 200-day moving average, reflecting an overall bullish market environment. Venus Remedies’ outperformance against this backdrop highlights its relative strength within the Pharmaceuticals & Biotechnology sector.
Momentum just kicked in! This Small Cap from the Auto - Trucks sector entered our list with explosive short-term signals. Catch the wave while it's still building!
- - Fresh momentum detected
- - Explosive short-term signals
- - Early wave positioning
Financial Highlights Supporting the Rally
Venus Remedies’ financial performance over the past year has been marked by significant growth in profitability and operational efficiency. The company’s net profit for the latest six months stood at Rs.29.73 crores, reflecting a growth of 528.54% compared to the previous period. Similarly, profit before tax excluding other income for the quarter reached Rs.24.78 crores, showing an increase of 2073.68%. These figures underscore a strong earnings momentum that has likely contributed to the stock’s upward price movement.
The company’s return on capital employed (ROCE) for the half year is recorded at 13.99%, the highest in its recent history, while the return on equity (ROE) stands at 10.5%. These ratios indicate efficient utilisation of capital and equity, factors that often attract investor attention in the pharmaceutical sector.
Venus Remedies maintains a low debt-to-equity ratio, averaging zero, which suggests a conservative capital structure and limited reliance on external borrowings. This financial prudence may have supported the stock’s appeal amid market volatility.
Valuation and Comparative Performance
The stock’s price-to-book value ratio is approximately 1.8, positioning it at a fair valuation relative to its peers and historical averages. Over the last year, Venus Remedies has delivered a total return of 140.01%, significantly outpacing the Sensex’s 3.35% return during the same period. This outperformance extends to longer time frames as well, with the stock exceeding the returns of the BSE500 index over the past three years, one year, and three months.
The company’s profit growth of 183% over the past year further complements its strong price performance, with a price/earnings to growth (PEG) ratio of 0.1, indicating that earnings growth has been substantial relative to the stock price movement.
Want to dive deeper on Venus Remedies ? There's a real-time research report diving right into the fundamentals, valuations, peer comparison, financials, technicals and much more!
- - Real-time research report
- - Complete fundamental analysis
- - Peer comparison included
Historical Price Range and Market Positioning
Venus Remedies’ 52-week low price was Rs.272.20, highlighting the substantial price appreciation to the current high of Rs.825. This wide price range over the year reflects a strong recovery and growth phase for the company’s stock. The pharmaceutical sector, known for its cyclical and regulatory influences, has seen Venus Remedies emerge as a notable outperformer within its industry segment.
Despite the company’s size and performance, domestic mutual funds currently hold no stake in Venus Remedies. This absence of mutual fund participation may reflect differing assessments of the stock’s valuation or business prospects among institutional investors.
Summary of Key Metrics
To summarise, Venus Remedies’ recent price action and financial results present a compelling picture of a stock that has reached a significant milestone. The new 52-week high of Rs.825 is supported by strong earnings growth, efficient capital utilisation, and a favourable technical setup. The stock’s outperformance relative to the Sensex and its sector peers further emphasises its momentum in the current market environment.
Investors and market watchers will note the alignment of positive financial indicators and technical signals that have propelled Venus Remedies to this new high, marking an important chapter in the company’s market journey.
Only for Rs. 14,999 - Get Access to 2 Years + 6 Months of All Premium Features on MarketsMojo. As low as ₹500/month! Claim 83% OFF →
